Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.7.0.1
Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Accrued expenses:    
Professional fees $ 1,450 $ 1,253
Salaries, bonuses and related benefits 3,532 2,846
Accrued Severance 0 53
Ovamed manufacturing rights - short term component 900 900
Research and development 680 394
Dr. Falk Pharma milestone 2,684 2,634
Other 1,874 2,002
Total accrued expenses 11,120 10,082
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 5,020 5,014
Total other long-term liabilities $ 5,020 $ 5,014